quote:Originally posted by hbomb: Anyone hear anything? Dropping to 25/26...do we need to bail?
I am sucking wind today...I dont DD most of the picks I post.... I ussually go we MOMO... what ever is moving at the time... And it can die real quick... If it is moving and it stalls i am ussualy outy unless there is news related, them I might wait for that 1st dip...
Unless you are willing to get out quick with a loss, i would not play my picks, you can not be asking people if is time to bail, you need to have that exit strategy when you open the position...
quote:Originally posted by hbomb: Anyone hear anything? Dropping to 25/26...do we need to bail?
I am sucking wind today...I dont DD most of the picks I post.... I ussually go we MOMO... what ever is moving at the time... And it can die real quick... If it is moving and it stalls i am ussualy outy unless there is news related, them I might wait for that 1st dip...
Unless you are willing to get out quick with a loss, i would not play my picks, you can not be asking people if is time to bail, you need to have that exit strategy when you open the position...
Take care and GLTY
Gotcha. I try to DD when I can. Momo picks can be great or they can suck (like this one)
IP: Logged |
posted
GenoMed, Inc. (Pink Sheets: GMED), a Next Generation Disease Management (DM) company whose business is public health(TM), announced today that it has obtained clearance, through their Indian distributor Sumit Biosciences Pvt Ltd, from the Indian Government to market its Next Generation DM(TM) product in India.
The cost is under US $150 per patient per year. Since the per capita income in India is around US $600 a year, GenoMed's Next Generation DM(TM) service is well within the reach of the average Indian citizen.
Sumit Biosciences Pvt Ltd is currently enlisting physicians at the King Edward Memorial Hospital in Mumbai to offer GenoMed's protocols to their patients. Mumbai, formerly called Bombay, is the fourth largest city in the world, with 12 million inhabitants.
Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "The US and Europe have been completely uninterested in our published methods for preventing kidney dialysis and slowing down emphysema. The $25 billion a year that the US spends on dialysis may actually serve as a perverse financial disincentive not to eliminate the industry. India spends nothing on dialysis, so nobody there has a financial stake in preserving the dialysis industry."
Added Dr. Moskowitz, "It's as if the Directors of the TB sanitaria in the US ignored streptomycin in 1950 to save their jobs. It's a shame that the taxpayers of the US and Europe are paying for genomics-based medicine, but citizens of developing countries like India are the only ones using it."
GenoMed is currently trading at $0.017 on volume of 608,700 shares.
About GenoMed
Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, http://www.genomed.com , by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.
-------------------- "Reality is the leading cause of stress amongst those in touch with it."
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
